In an effort to have SensoDx be a pioneer in novel universal diagnostics instrumentation, customized assay and software solutions and services for the individual wellness, hospital and research settings sectors, the firm is organized around development of state-of-the-art multi-parameteric point-of-care diagnostic solutions and wellness tools that deliver test information directly to patients and healthcare providers using intuitive mobile health (mHealth) interfaces. The effort is to change the current diagnostics paradigm that focuses on late stage disease diagnosis in traditional hospital settings to one that is anchored in consumer friendly testing venues using noninvasive sampling methods. Headed up by a recognized expert in the field of nanotechnology, his work made possible the high-volume micro/nano-manufacturing processes that are used to create fuel injection nozzle structures, inkjet print heads, medical diagnostic devices, and the CD-ROM., the SensoDx platform is based on the programmable bio-nano-chip technology -- an approach that is suitable for broad range of testing modalities including protein, antibody, general chemistry, drug/metabolite, oligonucleotide, cell counting, and cytology assays. The current SensoDx disease diagnostic portfolio encompasses cardiac heart disease, oral cancer, trauma, drugs of abuse, ovarian cancer and prostate cancer.This powerful chip-based technology has potential to empower individuals to play more active roles in management of their own healthcare and wellness needs.
